keyword
MENU ▼
Read by QxMD icon Read
search

Ranibizumab

keyword
https://www.readbyqxmd.com/read/28820850/ultrasonographic-findings-in-the-vitreous-of-patients-with-age-related-macular-degeneration-treated-with-intravitreal-anti-vascular-endothelial-growth-factor-injections
#1
Tamara Mato-Gondelle, Manuel F Bande, Laura Paniagua, María J Rodríguez-Cid, Maximino Abraldes, Maribel Fernández, María J Blanco-Teijeiro, Antonio Piñeiro
PURPOSE: We aimed to assess the relationship of repeated intravitreal injection of anti-vascular endothelial growth factor, the main treatment for exudative age-related macular degeneration, with changes in vitreous ultrasonographic findings in patients with age-related macular degeneration. METHODS: We retrospectively collected data from 41 patients (41 age-related macular degeneration eyes, 41 control eyes) on age, sex, number of injections, and type of anti-vascular endothelial growth factor (ranibizumab, aflibercept)...
August 16, 2017: Retina
https://www.readbyqxmd.com/read/28820848/ranibizumab-and-aflibercept-for-the-treatment-of-pigment-epithelial-detachment-in-neovascular-age-related-macular-degeneration-data-from-an-observational-study
#2
Anagha Vaze, Vuong Nguyen, Vincent Daien, Jennifer J Arnold, Stephanie H Young, Chui M Cheung, Ecosse Lamoureux, Mayuri Bhargava, Daniel Barthelmes, Mark C Gillies
PURPOSE: To assess the effect of intravitreal ranibizumab and aflibercept on retinal pigment epithelial detachment (RPED) in patients with neovascular age-related macular degeneration. METHODS: This was a retrospective analysis of data from a prospectively designed and implemented clinical audit. Analysis included change in RPED dimensions and visual acuity in 92/233 treatment-naive eyes with neovascular age-related macular degeneration and RPED 6 months after treatment with either aflibercept or ranibizumab...
August 16, 2017: Retina
https://www.readbyqxmd.com/read/28820169/aflibercept-for-recurrent-or-recalcitrant-polypoidal-choroidal-vasculopathy-in-indian-eyes-early-experience
#3
Aditya Bansal, Muna Bhende, Tarun Sharma, Pramod Bhende, Suchetana Mukherjee
Treatment guidelines for symptomatic polypoidal choroidal vasculopathy (PCV) have been described, but the management of recurrent or recalcitrant PCV is a challenge. The newer anti-vascular endothelial growth factor: aflibercept has shown promise in the treatment of both treatment naive and recalcitrant PCV in studies outside India. We present the minimum 6 months results of intravitreal aflibercept in recurrent and recalcitrant PCV in Indian eyes after multiple injections of bevacizumab/ranibizumab with or without photodynamic therapy...
August 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/28819823/inner-nuclear-layer-cystoid-spaces-are-a-poor-prognostic-factor-in-typical-age-related-macular-degeneration-and-polypoidal-choroidal-vasculopathy
#4
Eui Chun Kang, Seonghee Choi, Hyoung Jun Koh
PURPOSE: To investigate predictive factors for changes in best-corrected visual acuity (BCVA) at 24 months after intravitreal ranibizumab (IVR) for neovascular age-related macular degeneration (nAMD). METHODS: This retrospective study included 55 eyes of 55 consecutive patients (32 men and 23 women) with nAMD who received three consecutive monthly IVR injections and were re-treated as needed over a 24-month period. We used the mean changes in logarithm of the minimal angle of resolution (logMAR) BCVA at 24 months as the dependent variable in regression analysis...
August 17, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28819567/systemic-associations-with-residual-subretinal-fluid-after-ranibizumab-in-diabetic-macular-edema
#5
Meng-Ju Tsai, Yi-Ting Hsieh, Elizabeth P Shen, Yi-Jie Peng
PURPOSE: To investigate the impact of systemic diseases on the occurrence of subretinal fluid (SRF) in diabetic macular edema (DME) and prognostic factors for residual SRF following three consecutive monthly intravitreal ranibizumab. METHODS: Ninety-seven eyes from 68 patients with DME who completed 3 consecutive monthly injections of ranibizumab were enrolled. Systemic parameters mainly included chronic kidney disease (CKD), hypertension, HbA1c, and insulin dependence...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28814287/early-onset-coats-disease-initially-treated-as-unilateral-rop-at-39%C3%A2-weeks-postmenstrual-age-a-case-report
#6
Jie Peng, Qi Zhang, Chunli Chen, Qiujing Huang, Yian Li, Peiquan Zhao
BACKGROUND: This is the youngest case of Coats' disease, in terms of postmenstrual age (PMA), to be reported in the literature. This case highlights the remarkable variations in the clinical manifestations and the very early onset of Coats' disease. This case is unusual in both the age of onset and atypical clinical features, which resemble retinopathy of prematurity (ROP). CASE PRESENTATION: We report a case of a preterm boy born at 31 5/7 weeks gestational age who presented with atypical Coats' disease and was initially diagnosed as having ROP of only one eye at 39 weeks PMA...
August 16, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28811936/real-life-management-of-patients-with-retinal-vein-occlusion-using-i-macula-web-platform
#7
Massimo Nicolò, Monica Bonetto, Raffaella Rosa, Donatella Musetti, Maria Musolino, Carlo Enrico Traverso, Mauro Giacomini
AIM: Real-life evaluation in the management of patients affected by macular edema secondary to retinal vein occlusion. MATERIAL AND METHODS: A retrospective, observational study using the I-Macula Web platform. RESULTS: Thirty-five patients (37 eyes; 15 females and 20 male) affected by RVO were analysed. At 12 months, there was a statistically significant improvement of best-corrected visual acuity (p = 0.0235) and central macular thickness (p < 0...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28807635/sustained-benefits-of-ranibizumab-with-or-without-laser-in-branch-retinal-vein-occlusion-24-month-results-of-the-brighter-study
#8
Ramin Tadayoni, Sebastian M Waldstein, Francesco Boscia, Heinrich Gerding, Margarita Gekkieva, Elizabeth Barnes, Ayan Das Gupta, Andreas Wenzel, Ian Pearce
PURPOSE: To evaluate the long-term (24-month) efficacy and safety of ranibizumab 0.5 mg administered pro re nata (PRN) with or without laser using an individualized visual acuity (VA) stabilization criteria in patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO). DESIGN: Phase IIIb, open-label, randomized, active-controlled, 3-arm, multicenter study. PARTICIPANTS: A total of 455 patients. METHODS: Patients were randomized (2:2:1) to ranibizumab 0...
August 11, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28801117/incidence-and-outcomes-of-infectious-and-noninfectious-endophthalmitis-after-intravitreal-injections-for-age-related-macular-degeneration
#9
Vincent Daien, Vuong Nguyen, Rohan W Essex, Nigel Morlet, Daniel Barthelmes, Mark C Gillies
PURPOSE: To assess the incidence, cumulative rate, and long-term outcomes of infectious and noninfectious endophthalmitis after intravitreal injections (IVTs) of anti-vascular endothelial growth factor (VEGF) agents. DESIGN: Database study, prospectively designed. PARTICIPANTS: Treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) tracked by the Fight Retinal Blindness! (FRB!) registry that commenced anti-VEGF therapy between January 1, 2006, and November 30, 2016...
August 8, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28800629/protective-effects-on-the-retina-after-ranibizumab-treatment-in-an-ischemia-model
#10
Stephanie C Joachim, Marina Renner, Jacqueline Reinhard, Carsten Theiss, Caroline May, Stephanie Lohmann, Sabrina Reinehr, Gesa Stute, Andreas Faissner, Katrin Marcus, H Burkhard Dick
Retinal ischemia is common in eye disorders, like diabetic retinopathy or retinal vascular occlusion. The goal of this study was to evaluate the potential protective effects of an intravitreally injected vascular endothelial growth factor (VEGF) inhibitor (ranibizumab) on retinal cells in an ischemia animal model via immunohistochemistry (IF) and quantitative real-time PCR (PCR). A positive binding of ranibizumab to rat VEGF-A was confirmed via dot blot. One eye underwent ischemia and a subgroup received ranibizumab...
2017: PloS One
https://www.readbyqxmd.com/read/28796997/dynamics-of-inflammatory-factors-in-aqueous-humor-during-ranibizumab-or-aflibercept-treatment-for-age-related-macular-degeneration
#11
Ryosuke Motohashi, Hidetaka Noma, Kanako Yasuda, Osamu Kotake, Hiroshi Goto, Masahiko Shimura
PURPOSE: To evaluate the dynamic changes of the aqueous humor levels of inflammatory factors between patients receiving intravitreal ranibizumab injection (IRI) and aflibercept injection (IAI) in patients with exudative age-related macular degeneration (AMD). METHODS: The study was performed on 30 eyes with AMD that were scheduled to receive 3 doses of IRI (15 eyes) or IAI (15 eyes) at monthly intervals. Aqueous humor samples were collected when injection was done...
August 11, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28790804/treatment-of-myopic-choroidal-neovascularization-with-intravitreal-ranibizumab-injections-the-role-of-age
#12
Dimitrios Karagiannis, Georgios A Kontadakis, Konstantinos Kaprinis, Athanassios Giarmoukakis, Ilias Georgalas, Efstratios A Parikakis, Miltiadis K Tsilimbaris
PURPOSE: The aim of this study was to explore the role of age as a prognostic factor for the outcome of myopic choroidal neovascularization (CNV) treatment with intravitreal ranibizumab injections. METHODS: A retrospective review of charts of patients treated with intravitreal injections of ranibizumab for the treatment of myopic CNV was done. Patients with other ophthalmic disease were excluded. Patients were followed for at least 2 years. The correlation between age and the change in visual acuity and the number of injections during treatment was investigated...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28777388/choroidal-neovascularization-in-multifocal-choroiditis-after-dabrafenib-and-trametinib
#13
Giorgia C Albertini, Eleonora Corbelli, Maurizio Battaglia Parodi, Francesco Bandello
PURPOSE: To describe a case of bilateral choroidal neovascularization (CNV) in multifocal choroiditis (MFC) associated with dabrafenib and trametinib chemotherapy for metastatic melanoma. CASE: We present a case of a 57-year-old man with MFC who underwent combination therapy with dabrafenib plus trametinib for metastatic melanoma. The patient presented to our ophthalmology department complaining of bilateral vision loss of 2 days' duration. He underwent multimodal imaging showing a MFC reactivation complicated by bilateral CNV...
August 2, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28775088/bilateral-choroidal-neovascular-membrane-in-a-young-patient-with-sorsby-fundus-dystrophy-the-value-of-prompt-treatment
#14
Nardine Menassa, Sreekala Burgula, Theodoros Empeslidis, Konstantinos T Tsaousis
A 45-year-old man had developed a choroidal neovascular membrane (CNVM) in his left eye at the age of 38 years and had received six intravitreal ranibizumab injections with resulting visual acuities of 6/60 in the affected eye and 6/4 in the unaffected right eye (Snellen charts). Family history and genetic testing revealed tissue inhibitor of metalloproteinase-3 (TIMP3) gene positive Sorsby fundus dystrophy (SFD). The patient has been under regular follow-up since. At the age of 45 years, he presented with subretinal fluid accumulation in his right eye suggestive of CNVM and received six intravitreal ranibizumab injections, which maintained visual acuity of 6/7...
August 3, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28772268/baseline-optical-coherence-tomography-findings-as-outcome-predictors-after-switching-from-ranibizumab-to-aflibercept-in-neovascular-age-related-macular-degeneration-following-a-treat-and-extend-regimen
#15
Cengiz Türksever, Christian Prünte, Katja Hatz
PURPOSE: To evaluate outcome predictors of aflibercept in neovascular age-related macular degeneration pretreated with ranibizumab based on a treat-and-extend regimen (TER). METHODS: We performed a retrospective evaluation of 18-month follow-up of 45 consecutive patients with limited response to ranibizumab. RESULTS: At month 18, mean central retinal thickness and intraretinal fluid (IRF) height were significantly reduced. The recurrence-free treatment interval (RFTI) increased from 7...
August 4, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28767550/impact-of-long-term-intravitreal-anti-vascular-endothelial-growth-factor-on-preexisting-microstructural-alterations-in-diabetic-macular-edema
#16
Magdalena A Wirth, Juliana Wons, Florentina J Freiberg, Matthias D Becker, Stephan Michels
PURPOSE: Evaluation of the influence of long-term intravitreal anti-vascular endothelial growth factor treatment on preexisting retinal microstructural alterations in patients with diabetic macular edema. METHODS: Eyes with diabetic macular edema and a history of ≥ 20 intravitreal anti-vascular endothelial growth factor (aflibercept and/or ranibizumab) injections were included in this retrospective study. Primary outcome was the extent of disorganization of retinal inner layers, alterations at the outer plexiform layer/Henle fiber layer junction, disruption of external limiting membrane/ellipsoid zone, disruption of retinal pigment epithelium/Bruch complex, and retinal atrophy at baseline versus after ≥ 20 intravitreal injections as visualized by spectral-domain optical coherence tomography images...
August 1, 2017: Retina
https://www.readbyqxmd.com/read/28765149/changes-in-multiple-cytokine-concentrations-in-the-aqueous-humour-of-neovascular-age-related-macular-degeneration-after-2-months-of-ranibizumab-therapy
#17
Shinichi Sakamoto, Hidenori Takahashi, Xue Tan, Yuji Inoue, Yoko Nomura, Yusuke Arai, Yujiro Fujino, Hidetoshi Kawashima, Yasuo Yanagi
PURPOSE: To determine changes in multiple cytokine concentrations in the anterior chamber during the induction phase of ranibizumab treatment in patients with neovascular age-related macular degeneration (AMD). METHODS: This prospective study included 48 treatment-naïve neovascular AMD eyes of 48 patients who received three consecutive monthly injections of ranibizumab at the Japan Community Health Care Organization Tokyo Shinjuku Medical Center between November 2010 and August 2012...
August 1, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28758110/comparisons-of-efficacy-of-intravitreal-aflibercept-and-ranibizumab-in-eyes-with-diabetic-macular-edema
#18
Norihiro Shimizu, Toshiyuki Oshitari, Tomoaki Tatsumi, Yoko Takatsuna, Miyuki Arai, Eiju Sato, Takayuki Baba, Shuichi Yamamoto
We compared the efficacy of intravitreal aflibercept (IVA) to intravitreal ranibizumab (IVR) injections in eyes with diabetic macular edema (DME). The medical records of 49 eyes of 36 patients who were diagnosed with DME and had received IVR and 46 eyes of 40 patients who had received IVA treatment were reviewed. The central macular thickness (CMT) and best-corrected visual acuity (BCVA) were measured at the baseline and at 1, 3, and 6 months after the IVR or IVA. The mean number of injections of IVR was 2...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28756707/emerging-vascular-endothelial-growth-factor-antagonists-to-treat-neovascular-age-related-macular-degeneration
#19
Rehan M Hussain, Thomas A Ciulla
Evolving anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration (nAMD) include long acting agents, combination strategies involving new pathways, topical agents, sustained-release, and genetic therapy strategies. Areas covered: Brolucizumab and abicipar pegol have smaller molecular size, facilitating higher concentrations and potentially longer duration than current anti-VEGF agents. Agents being combined with anti-VEGFs include OPT-302 (to inhibit VEGF-C and VEGF-D); pegpleranib and rinucumab (to inhibit platelet derived growth factor, PDGF - but both failed to show consistently improved visual outcomes compared to anti-VEGF monotherapy); and RG7716, ARP-1536 and nesvacumab (to activate the Tie-2 tyrosine kinase receptor, which reduces permeability)...
August 4, 2017: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/28756595/structural-and-functional-assessment-after-intravitreal-injection-of-ranibizumab-in-diabetic-macular-edema
#20
YuDong Fu, Ping Wang, XuXia Meng, Zhaodong Du, DaBo Wang
PURPOSE: To evaluate structure and function improvement in central retina by optical coherence tomography (OCT) and multifocal electroretinography (mf-ERG) in diabetic macular edema (DME) patients after intravitreal injection of ranibizumab (IVR) treatment. METHODS: Twenty-seven eyes in 27 patients with DME received three consecutive monthly injections of IVR (0.05 ml, 10 mg/ml) and as needed thereafter. The clinical parameters of best-corrected visual acuity (BCVA), central foveal thickness (CFT) and mf-ERG were monitored for 6 months before and after IVR...
July 29, 2017: Documenta Ophthalmologica. Advances in Ophthalmology
keyword
keyword
1767
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"